A multicenter, randomized trial combining CTLA-4 inhibition (ipilimumab) and sargramostim for the treatment of advanced melanoma was performed by Hodi et al. (ECOG 1608) (Table 4) [99]. The gene discussed is CTLA4; the disease is melanoma.